Currently Viewing:
Newsroom
Currently Reading
CRISPR-Gene Editing Technology Successfully Treated Lethal Lung Disease in Animal Models
April 20, 2019 – Samantha DiGrande
Study Finds Patients Misdiagnosed With MS Increases Morbidity, Healthcare Costs
April 19, 2019 – Samantha DiGrande
Sensor-based Algorithm Detects Patient Response to Parkinson Therapies
April 19, 2019 – Samantha DiGrande
Analyzing the Scent of Parkinson Disease Could Lead to Diagnostic Tool
April 19, 2019 – Wallace Stephens
This Week in Managed Care: April 19, 2019
April 19, 2019
ctDNA Can Detect MRD and Early Cancer Recurrence in Colorectal Cancer
April 19, 2019 – Laura Joszt
5 Findings From the April 2019 Issue of AJMC®
April 19, 2019 – Christina Mattina
What We're Reading: Long-Term Care Benefits; Predicting Obesity; Montana Reauthorizes Medicaid Expansion
April 19, 2019 – AJMC Staff
AJMC® in the Press, April 19, 2019
April 19, 2019 – AJMC Staff

FDA Broadens the Spectrum for Evaluating Treatments for Opioid Use Disorder

Jaime Rosenberg
Instead of assessing a treatment’s impact solely on reductions in opioid use, the agency will take into account the effect of the treatment on things like emergency room admissions and infectious disease transmissions.
In an effort to encourage the development of novel treatments for opioid use disorder, the FDA is expanding the way it evaluates the effectiveness and benefit of medication-assisted treatment (MAT) products.

Instead of assessing a treatment’s impact solely on reductions in opioid use, the agency will take into account the effect of the treatment on things like emergency room admissions and infectious disease transmissions.

“Treatments that can impact these aspects of addiction can be important parts of a comprehensive approach to the treatment of opioid use disorder,” said FDA Commissioner Scott Gottlieb, MD, in a statement. “This new guidance is an important step in fostering the development of new treatment options that help patients achieve these and other real-world outcomes, by providing a pathway for how innovators can use these clinically relevant measures as part of new drug development programs.”

MAT utilizes prescription drugs, such as buprenorphine, methadone, and naltrexone, to stabilize brain chemistry; reduce or block the euphoric effects of opioids; reduce the desire to use opioids; and normalize body functions.

The treatment is combined with counseling and other behavioral therapies as a comprehensive approach to treating patients with opioid use disorder. Regular adherence to MAT has demonstrated reductions in opioid withdrawal symptoms and cuts the risk of mortality from all causes in half.

The new draft guidance pinpoints several clinical endpoints for developers to utilize in addition to or rather than the current reduction in drug use. The effectiveness of the treatment can be measured by its impact on adverse outcomes, such as mortality (overall mortality or overdose mortality), emergency medical interventions, and Hepatitis C transmission.

Improvements in the ability to go back to school, work, or other productive activities may also serve as clinical benefits. There is also potential for patient-reported experiences, such as an urge to use opioids, to complement other endpoints.

With a broader spectrum of endpoints, the FDA noted that this could require larger clinical trials than typically conducted and encouraged sponsors to discuss their plans with the agency early in the drug development process.

While underscoring the importance of ensuring access to these treatments, Gottlieb also highlighted the need to address the stigma surrounding MAT. “We’re committed to doing our part to expand access to high-quality, effective MATs and encouraging healthcare professionals to ensure patients with opioid use disorder are offered an adequate chance to benefit from these therapies,” he said in a statement. “This work also includes improving understanding about the treatment options available for patients and countering the unfortunate stigma that’s sometimes associated with their use.

This push toward encouraging the development of MAT products comes shortly after the FDA’s approval of the first generic version of Subuxone (buprenorphine and naloxone) sublingual film and their reaffirmed commitment to improving access to prevention, treatment, and recovery options for those with opioid use disorder.

Related Articles

FDA Approves First Generic Version of Suboxone for Opioid Dependence
Dr Dennis P. Scanlon Explains Costs Associated With the Opioid Epidemic
Technology, Data Are No Silver Bullets, but Can Help Turn the Tide of the Opioid Epidemic
Health Centers Key in Addressing Opioid Epidemic, and Medicaid Is Crucial, Kaiser Finds
 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up